Addressing gaps in treatment of AMD

Video

Aleksandra Rachitskaya, MD, speaks on the current gaps in AMD treatment as well as ongoing retinal advancements to help address unmeet needs of patients.

Current Time 0:00
Duration 3:30
Loaded: 4.69%
Stream Type LIVE
Remaining Time 3:30
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Aleksandra Rachitskaya, MD, retinal specialist of the Cole Eye Institute, Cleveland Clinic,speaks on the current gaps in AMD treatment as well as ongoing retinal advancements in work to help address unmeet needs of patients.

    See more AMD Awareness content here, here, and here.

    Newsletter

    Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

    Subscribe Now!
    Recent Videos
    Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
    ARVO 2025: Ocular and systemic mitochondrial diseases may be key to dementia diagnosis
    Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
    ARVO 2025: Alfredo Sadun, MD, PhD, says "later is better" for some LHON interventions
    At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
    ARVO 2025: Nitish Mehta, MD, provides real-world insights from aflibercept 8 mg for treatment-naive diabetic macular oedema
    ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
    ARVO 2025: Anat Loewenstein, MD, and colleagues on meeting needs of patients with diabetic retinopathy
    A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
    A panel discussion on extended treatment intervals in retinal therapy breaks the mold at COPHy 2025
    Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
    How embracing opposition sends clinicians home from COPHy with more useful takeaways
    3 experts are featured in this series.
    Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies
    Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
    Angiogenesis 2025: The global forecast for AI-driven home OCT
    3 experts are featured in this series.
    Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients
    3 experts are featured in this series.
    Perspectives on the Usefulness of Real-world Data
    Related Content
    The Agência de vigilância Sanitária (ANVISA) in Brazil. Concept image for pharmaceutical approval, Lucentis ranibizumab biosimilar ranivisio FYB201. Image credit: ©Rmcarvalhobsb – stock.adobe.com

    Brazil’s ANVISA grants marketing authorisation to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)

    Lynda Charters
    June 5th 2025
    Article

    The biopharmaceutical is the first biosimilar to ranibizumab (Genentech Inc.) approved in Brazil

    PHOTON Results and Their Relation to DME Patients in Your Practice

    PHOTON Results and Their Relation to DME Patients in Your Practice

    July 25th 2024
    Podcast

    John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

    A person types on a computer. An AI brain is over the screen. Concept image for artificial intelligence, therapy planning assistant system, TPS, Europe, CE mark. Image credit: ©New Africa – stock.adobe.com

    EU issues CE mark for AI therapy planning assistant from deepeye Medical

    Jordana Joy
    June 2nd 2025
    Article

    The therapy planning support tool has been trained on thousands of patient cases from more than 200 retina centres throughout Europe

    PULSAR Results and Their Relation to nAMD Patients in Your Practice

    PULSAR Results and Their Relation to nAMD Patients in Your Practice

    July 24th 2024
    Podcast

    John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

    An image of two containers of vitamin B supplements. Concept image for choline, b6, b9 and b12 vitamins in neuroprotection for glaucoma. ©itsflowingtothesoul – stock.adobe.com

    Research indicates B vitamins and choline provide neuroprotection against glaucoma

    Lynda Charters
    May 26th 2025
    Article

    Vitamins B6, B9 and B12 were found to be neuroprotective against retinal ganglion cell death

    A single-shot, 130-degree OCTA image of the retina captured using DREAM OCT. Image courtesy of Intalight

    EMA issues CE mark for DREAM OCT (Intalight)

    Jordana Joy
    May 22nd 2025
    Article

    The OCT platform offers deep imaging depth, rapid sweeping speed, extensive scan range, accurate results and multimodal imaging capabilities

    © 2025 MJH Life Sciences

    All rights reserved.